BMO Capital Upgrades Nektar Therapeutics (NKTR) to Outperform

September 22, 2009 9:26 AM EDT
Get Alerts NKTR Hot Sheet
Price: $13.10 -1.8%

Rating Summary:
    9 Buy, 1 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade NKTR Now!
Join SI Premium – FREE
BMO Capital upgrades Nektar Therapeutics (Nasdaq: NKTR) from Market Perform to Outperform. Price target $12.

To see more analyst ratings on NKTR Click Here.

Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.

You May Also Be Interested In

Related Categories


Related Entities

BMO Capital

Add Your Comment